Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils

CONCLUSIONS: Dupilumab treatment significantly reduced annualized severe exacerbation rates and improved lung function in patients with uncontrolled, moderate-to-severe, type 2 asthma, irrespective of baseline blood neutrophil count. This trial is registered with NCT02414854.PMID:37901346 | PMC:PMC10602700 | DOI:10.1155/2023/9943584

Source: Journal of Immunology Research - October 30, 2023 Category: Allergy & Immunology Authors: Eugene R Bleecker Reynold A Panettieri Njira L Lugogo Jonathan Corren Nadia Daizadeh Juby A Jacob-Nara Yamo Deniz Paul J Rowe Angela Khodzhayev Xavier Soler Thomas J Ferro Christopher N Hansen Source Type: research